Item 1.
|
Security and Issuer
.
|
This Amendment No. 2 (the "Amendment No. 2") to the statement filed on Schedule 13D filed on November 10, 2015 (the "Original 13D"), as amended by Amendment No. 1 (the "Amendment No. 1") to the Original 13D filed on July 7, 2017, relating to the Common Stock, $0.0001 par value per share (the "Common Stock"), of Adesto Technologies Corporation (the "Issuer") having its principal executive office at 3600 Peterson Way, Santa Clara, CA 95054, amends the Original 13D as set forth herein.
Certain terms used, but not defined, in this Amendment No. 2 shall have the meanings assigned thereto in the Original 13D (as amended by Amendment No. 1). Except as specifically provided herein, this Amendment No. 2 does not modify any of the information previously reported in the Original 13D or Amendment No. 1.
Item 2.
|
Identity and Background
.
|
|
(a)
|
This statement is being filed by: (1) ARCH Venture Fund VI, L.P. ("ARCH Venture Fund VI"), (2) ARCH Venture Partners VI, L.P. ("AVP VI LP"), which is the sole general partner of ARCH Venture Fund VI, (3) ARCH Venture Partners VI, LLC ("AVP VI LLC"), which is the sole general partner of AVP VI LP, (4) Clinton Bybee ("Bybee"), (5) Keith Crandell ("Crandell"), and (6) Robert Nelsen ("Nelsen" and, together with Bybee and Crandell, collectively, the "Managing Directors" and each individually, a "Managing Director"). Each of the individuals and entities above shall be referred to herein individually as a "Reporting Person" and collectively as the "Reporting Persons".
|
|
(b)
|
The business address of each of the Reporting Persons is
8755 West Higgins Road, Suite 1025,
Chicago, IL, 60631.
|
|
(c)
|
The principal business of ARCH Venture Fund VI is to invest and assist in developmental and emerging businesses located principally in the United States. The principal business of AVP VI LP is to act as the general partner of ARCH Venture Fund VI. The principal business of AVP VI LLC is to act as the general partner of AVP VI LP. The principal business of each of the Managing Directors is to act as managing directors of AVP VI LLC and a number of affiliated partnerships with similar businesses.
|
|
(d)
|
During the five years prior to the date hereof, none of the Reporting Persons has been convicted in a criminal proceeding.
|
|
(e)
|
During the five years prior to the date hereof, none of the Reporting Persons has been a party to a civil proceeding of a judicial or administrative body of competent jurisdiction ending in a judgment, decree or final order enjoining future violations of, or prohibiting or mandating activities subject to, Federal or State securities laws or finding any violation with respect to such laws.
|
|
(f)
|
Each of ARCH Venture Fund VI and AVP VI LP is a Delaware limited partnership. AVP VI LLC is a Delaware limited liability company. Each of the Managing Directors is a United States citizen.
|
CUSIP No. 00687D 101
|
Schedule 13D
|
Page 9 of 11
|
Item 5.
|
Interest in Securities of the Issuer
.
|
Item 5 of the Original 13D is hereby amended and restated in its entirety as follows:
(a)
|
ARCH Venture Fund VI is the record owner of 2,276,511 shares of Common Stock (the "Record Shares").
|
(b)
|
AVP VI LP, as the sole general partner of ARCH Venture Fund VI, may be deemed to beneficially own the Record Shares. AVP VI LLC, as the sole general partner of AVP VI LP, may be deemed to beneficially own the Record Shares.
|
In addition, each of the Managing Directors may be deemed to share the power to direct the disposition and vote of the Record Shares. Each Reporting Person disclaims beneficial ownership of all securities except for the shares, if any, held of record by such Reporting Person. As of the date of this filing, Crandell is the holder of 14,491 shares of Common Stock (the "Crandell Additional Shares").
The percentage of outstanding Common Stock of the Issuer which may be deemed to be beneficially owned by each Reporting Person is set forth on Line 13 of such Reporting Person's cover sheet. Such percentage was calculated based upon 29,268,482 shares of Common Stock outstanding as of July 23, 2018, as reported on the Issuer's quarterly report filed on Form 10-Q with the Securities and Exchange Commission on August 9, 2018. For Crandell, the percentage set forth on Crandell's cover sheet was calculated using the Record Shares and Crandell Additional Shares.
(c)
|
Regarding the number of shares as to which such person has:
|
|
(i)
|
sole power to vote or to direct the vote: See line 7 of cover sheets.
|
|
(ii)
|
shared power to vote or to direct the vote: See line 8 of cover sheets.
|
|
(iii)
|
sole power to dispose or to direct the disposition: See line 9 of cover sheets.
|
|
(iv)
|
shared power to dispose or to direct the disposition: See line 10 of cover sheets.
|
(d)
|
Except as set forth above, none of the Reporting Persons has effected any transaction in the Common Stock during the last 60 days.
|
|
(e)
|
No other person is known to have the right to receive or the power to direct the receipt of dividends from, or any proceeds from the sale of, shares beneficially owned by any of the Reporting Persons.
|
Item 7.
|
Material to be Filed as Exhibits
.
|
Exhibit 1 – Agreement regarding filing of joint Schedule 13D.
CUSIP No. 00687D 101
|
Schedule 13D
|
Page 10 of 11
|
SIGNATURE
After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.
Date:
August 31, 2018
ARCH VENTURE FUND VI, L.P.
By: ARCH Venture Partners VI, L.P.
its General Partner
By: ARCH Venture Partners VI, LLC
its General Partner
By:
*
Managing Director
ARCH VENTURE PARTNERS VI, L.P.
By: ARCH Venture Partners VI, LLC
its General Partner
By:
*
Managing Director
ARCH VENTURE PARTNERS VI, LLC
By:
*
Managing Director
*
Clinton Bybee
*
Keith Crandell
*
Robert Nelsen
* By:
/s/ Mark McDonnell
Mark McDonnell as Attorney-in-Fact
*
This Amendment No. 2 to Schedule 13D was executed by Mark McDonnell pursuant to a Power of Attorney filed as Exhibit 24 to the Form 3 relating to the beneficial ownership of shares of Fate Therapeutics, Inc. (FATE) by the Reporting Persons filed with the Securities Exchange Commission on September 30, 2013 and incorporated herein in its entirety by reference.
CUSIP No. 00687D 101
|
Schedule 13D
|
Page 11 of 11
|
Exhibit 1
AGREEMENT OF JOINT FILING
Pursuant to Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, the undersigned hereby agree that only one statement containing the information required by Schedule 13D need be filed with respect to the ownership by each of the undersigned of shares of Common Stock of Adesto Technologies Corporation.
This Agreement may be executed in any number of counterparts, each of which shall be deemed an original.
Date:
August 31, 2018